Navigation Links
AIDS researchers isolate new potent and broadly effective antibodies against HIV
Date:8/17/2011

bNAbs from separate blood samples using an entirely different approach.

Both the previous and current studies used Theraclone Science's highly sensitive I-STAR technology to isolate the antibodies. The new crop of bNAbs, like PG9 and PG16, was rescued from cell cultures derived from single antibody-producing B cells used for antibody discovery and development. Theraclone Sciences Executive Chair and Interim CEO, Steven Gillis commented, "We're delighted that I-STAR has provided essential support in identifying bNAbs that will contribute to advancing AIDS vaccine development. In this project, and in our own infectious disease and cancer programs, the I-STAR platform continues to demonstrate a remarkably powerful ability to isolate rare antibodies with unique properties. Theraclone values these collaborative opportunities in which I-STAR can be used to help improve treatment for critical diseases."

Monogram Biosciences, which also participated in the discovery of PG9 and PG16, conducted the neutralization assays essential to isolating the new bNAbs. The serum samples from which they were isolated represent the top 1% of all such samples gathered by IAVI and its partners, in terms of the number of HIV variants they neutralize and the potency with which they do so.

"Monogram has developed a highly skilled scientific team capable of taking on a variety of biomedical challenges," said Chris Petropoulos, Vice President, Laboratory Corporation of America Holdings, Research and Development, Monogram Biosciences. "Their expertise and innovation has been invaluable to the discovery of these new antibodies. This research illustrates the important role different sectors of the research and health care community can play in supporting global health initiatives."

The analysis of the new antibodies also hints at how future vaccines ought to be formulated to maximize their effectiveness. On the basis of their analyses, the authors of the report
'/>"/>

Contact: Lauren Wesolowski
lwesolowski@iavi.org
212-328-7420
International AIDS Vaccine Initiative
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Pitt cancer researchers find key oncoprotein in Merkel cell carcinoma
2. Researchers create new experimental vaccine against chikungunya virus
3. USF researchers get $2.6 million NIH grant to investigate new post-stroke therapy
4. Childrens National collaborates with NIH researchers to identify gene variant in Proteus syndrome
5. Penn researchers describe key molecule that keeps immune cell development on track
6. Researchers find way to help donor adult blood stem cells overcome transplant rejection
7. UGA researchers use gold nanoparticles to diagnose flu in minutes
8. Researchers develop and test new molecule as a delivery vehicle to image and kill brain tumors
9. Stomach Cancer Tumors Have Genetic Differences: Researchers
10. Traumatic brain injury: NIH-funded researchers will assess biomarkers for diagnosis and treatment
11. Researchers map minority microbes in the colon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... MMAR Medical is pleased to announce their ... regular customers to enjoy several perks and benefits when ... wholesale license. It’s a great choice for independent athletes, ... who regularly purchase medical braces but could use a ... active lifestyle or those of your club, group or ...
(Date:8/28/2014)... The need for larger space has become more ... The new location - 4700 Bryant Irvin Court, Fort Worth, ... space than TLC had in the past, as well as ... our new location because it represents a good fit for ... in size compared to the current one, the building itself ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 Aeroflow ... to acquire as part of a strategic expansion ... is positioned for taking ownership of new businesses ... increase economies of scale. , Last week, the ... with Hometown Respiratory to increase service in the ...
(Date:8/27/2014)... 2014 According to a new market ... Market (Neurosurgical Navigation Systems, ENT Navigation Systems and Orthopedic ... Trends and Forecast 2014 - 2020", the global surgical ... in 2013 and is expected to grow at a ... an estimated value of USD 295.5 million in 2020. ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 DiaSorin has ... Utility of 1,25 Dihydroxyvitamin D,” will feature guest speaker ... Penny George Institute for Health and Healing Integrative Medicine. ... the Penny George Institute for Health and Healing and ... Health Care, Minneapolis, Minnesota. He also serves as a ...
Breaking Medicine News(10 mins):Health News:MMAR Medical Announces Customer Membership Program 2Health News:Aeroflow Healthcare Seeks Strategic Acquisition Opportunities 2Health News:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Health News:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 2Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 3
... gives new meaning to the word transformative, researchers from ... are integrating some of the best practices of industry ... propel the development of innovative cancer treatments from the ... Cancer Center has initiated the Translational Research Acceleration Collaboration ...
... Foundation for a,Healthy Florida, the philanthropic affiliate of ... approved $951,486 in grants to be awarded this,winter ... needs in their communities., "The Blue Foundation ... to quality health-related services for Floridians who are ...
... lives could be,saved over the next five years through ... the 30 hardest hit countries in,Africa, according to a ... rapid scale-up would increase annual economic output,by as much ... cases, and,free up 427,000 needed hospital beds over five ...
... MIAMI, Jan. 25 OPKO Health, Inc. (Amex: ... and Richard C.,Pfenniger, Jr. to its Board of Directors. ... David Eichler. Mr. Pfenniger was,appointed to fill the vacancy ... a newly created Board position., "The addition of ...
... Calif., Jan. 25 IPC The,Hospitalist Company, Inc. (Nasdaq: ... yesterday the initial public offering of 5,200,000,shares of its ... $16.00 per share.,The Company has agreed to sell 3,300,000 ... to sell the remaining 1,900,000 shares of,common stock. The ...
... as 30,000 deaths each year, study says , , FRIDAY, ... greatly reduce their risk of developing ovarian cancer, and the ... study confirms. , The use of oral contraceptives has long ... The authors of the new study say their findings show ...
Cached Medicine News:Health News:ITRAC on track and bridging gap between academic research and applied discovery 2Health News:ITRAC on track and bridging gap between academic research and applied discovery 3Health News:Eleven Florida Nonprofit Organizations to Receive Grants Totaling Nearly $1 Million From The Blue Foundation 2Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 2Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 3Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 4Health News:OPKO Health Announces Changes to Board of Directors 2Health News:OPKO Health Announces Changes to Board of Directors 3Health News:IPC The Hospitalist Company, Inc. Prices Initial Public Offering 2Health News:Oral Contraceptives Cut Ovarian Cancer Risk 2Health News:Oral Contraceptives Cut Ovarian Cancer Risk 3
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Orthopedic Soft ... http://www.reportlinker.com/p02316671/Global-Orthopedic-Soft-Tissue-Repair-Devices-Market-2014-2018.html About Orthopedic ... the mass of cells that connect, support, or ... soft tissues such as tendons, ligaments, cartilage, fascia, ...
(Date:8/27/2014)... 2014 Decision Resources Group finds that the ... Memphis health system and hospital sector in ... rivals Methodist Le Bonheur Healthcare and Baptist Memorial Health ... patient care. In addition, a national contract recently signed ... plan enrollment in the Memphis ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... available in its catalogue: Global Heart ... http://www.reportlinker.com/p02316644/Global-Heart-Valve-Repair-and-Replacement-Market-2014-2018.html About Heart ... in the human heart which control the flow ... affected with heart valve diseases such as valvular ...
Breaking Medicine Technology:Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 3Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 5Memphis-area Health Systems Turn Attention to Clinical Integration 2Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4
... 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) today ... to the pivotal Phase II trial of its lead ... novo poor-risk acute myelogenous leukemia (AML). Alan Kessman, ... reached this milestone in the pivotal Phase II trial ...
... Study to Explore the Efficacy of Novel Proteasome Inhibitor ... Patients with Relapsed and Refractory Multiple Myeloma, SOUTH ... Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today,announced ... Phase 2,clinical trial to study Proteolix,s potent and selective ...
Cached Medicine Technology:Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 2Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 3Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 4The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 2The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 3The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 4
... on Smart Cards. Insert the card and turn ... turns itself off after the programmed time. The ... of treatments. Simply provide your patient with the ... progress on the next visit.,The initial set of ...
... battery operated dual-channel therapy system designed for use ... 4 Conti also includes a programme for treating ... 4 Conti provokes a contraction of the pelvic ... muscles need exercising. In URGE incontinence, ELPHA 4 ...
... disposable template is designed for ... eliminate the need for cleaning. ... premium silicone molded over a ... needle placement while maintaining needle ...
... is designed for use with the ... prostate brachytherapy. Please be sure that ... the graphics on the Reusable Template. ... from lower surface which fits into ...
Medicine Products: